CT-BASED DEFINITION AND STRUCTURED REPORTING OF ABDOMINAL LYMPH NODE STATIONS





Lutetium-177-Prostate-Specific Membrane Antigen Radioligand Therapy: What Is the Value of Post-Therapeutic Imaging?

Lutetium-177 (Lu-177)-labelled radioligand therapies (RLT) targeting prostate-specific membrane antigen (PSMA) present a promising treatment for patients with progressive metastasized castration-resistant prostate cancer (mCRPC).Personalized dosimetry, facilitated by post-therapeutic imaging, offers the potential to enhance treatment efficacy by cu

read more